Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
Status:
Active, not recruiting
Trial end date:
2024-05-24
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and tolerability of bintrafusp alfa in combination with
other anti-cancer therapies in participants with locally advanced or advanced cervical
cancer.